mf59
Small moleculeexperimental
Clinical trial activity
21 trials · 40 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
11
Phase 3
2
Phase 4
1
Earliest trial started Apr 1, 2011 (NCT01342796)
Timeline
Indications
Approved for
Studied for
- COVID-19 · Phase 1
- Healthy Volunteers · Phase 2
- HIV Infections · Phase 1/Phase 2
- Humans · Phase 2
- Infections · Phase 1
- Influenza A Virus, H5N1 Subtype · Phase 2
- Influenza, Human · Phase 4
- Influenza in Birds · Phase 2
- Influenza Vaccines · Phase 2
- Organ Transplantation · Phase 2/Phase 3
- Respiratory Tract Infections · Phase 1
- SARS-CoV-2 · Phase 1
- Virus Diseases · Phase 1
Mechanism of action
- Unspecified targetImmunity, active
immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mf59c.1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07126652 | N/A | Oct 1, 2025 | National Taiwan University |
| NCT06560151 | Phase 2 | Aug 21, 2024 | Department of Health and Human Services, ICON, Rho, Inc. |
| NCT05875961 | Phase 1 | Jun 15, 2023 | CSL Behring, Department of Health and Human Services |
| NCT05608005 | Phase 2 | Nov 3, 2022 | Sanofi-Aventis |
| NCT05664334 | Phase 1 | Sep 21, 2022 | Icosavax, Inc. |
| NCT05035680 | Phase 1 | Apr 14, 2022 | Bill and Melinda Gates Foundation, IQVIA |
| NCT05272605 | Phase 1 | Apr 5, 2022 | Southern Star Research Pty Ltd., University of Melbourne |
| NCT04782323 | Phase 2 | Apr 13, 2021 | CSL Behring |
| NCT04669691 | Phase 2 | Dec 18, 2020 | CSL Behring |
| NCT04576702 | Phase 2 | Oct 8, 2020 | CSL Behring |
| NCT04495933 | Phase 1 | Jul 13, 2020 | Coalition for Epidemic Preparedness Innovations, Nucleus Network Ltd, Syneos Health, University of Queensland |
| NCT03699839 | Phase 2/Phase 3 (Phase 3) | Oct 26, 2018 | Cantonal Hospital of St. Gallen, Fondazione Epatocentro Ticino, University of Basel, University of Bern, University of Geneva, University of Lausanne, University of Zurich |
| NCT03682120 | Phase 2 | Oct 8, 2018 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT03669627 | Phase 2 | Sep 30, 2018 | Canadian Center for Vaccinology, Dalhousie University, Laval University, McGill University, McMaster University, Provincial Health Services Authority, University of British Columbia, University of Montreal |
| NCT03497845 | Phase 2 | Mar 15, 2018 | Department of Health and Human Services |
| NCT03314662 | Phase 3 | Oct 17, 2017 | CSL Behring |
| NCT03330132 | Phase 4 | Oct 7, 2017 | Centers for Disease Control and Prevention (CDC), The University of Hong Kong |
| NCT03284710 | Phase 1/Phase 2 (Phase 2) | Jun 19, 2017 | Centre for the AIDS Programme of Research in South Africa, GlaxoSmithKline, HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), Sanofi-Aventis, University of Alabama, Birmingham |
| NCT01423825 | Phase 1 | Aug 1, 2011 | National Institute of Allergy and Infectious Diseases (NIAID), University of the Witwatersrand |
| NCT01376726 | Phase 1 | Jul 1, 2011 | Emory University, National Institute of Allergy and Infectious Diseases (NIAID), Novartis |
Showing 20 of 21 trials
Page 1 / 2
Organizations
Research & Development (40)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CSL Behring | For profit | 5 | 5 | 3 | 2017 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 4 | 4 | 2 | 2011 |
| Department of Health and Human Services | Government | 3 | 2 | 2 | 2018 |
| Novartis | For profit | 2 | 1 | 2 | 2011 |
| Sanofi-Aventis | For profit | 2 | 1 | 1 | 2017 |
| Bill and Melinda Gates Foundation | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Canadian Center for Vaccinology | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Cantonal Hospital of St. Gallen | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Centers for Disease Control and Prevention (CDC) | Government | 1 | 0 | 1 | 2017 |
| Centre for the AIDS Programme of Research in South Africa | Government | 1 | 0 | 1 | 2017 |
| Coalition for Epidemic Preparedness Innovations | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Dalhousie University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Emory University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Fondazione Epatocentro Ticino | Academic/Hospital | 1 | 0 | 1 | 2018 |
| GlaxoSmithKline | For profit | 1 | 0 | 1 | 2017 |
| HIV Vaccine Trials Network | Academic/Hospital | 1 | 0 | 1 | 2017 |
| ICON | For profit | 1 | 0 | 1 | 2024 |
| Icosavax, Inc. | For profit | 1 | 1 | 1 | 2022 |
| IQVIA | For profit | 1 | 0 | 1 | 2022 |
| Laval University | Academic/Hospital | 1 | 0 | 1 | 2018 |
40 organizations
Page 1 / 2